Articles with "cts5" as a keyword



Photo by aaronburden from unsplash

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

Sign Up to like & get
recommendations!
Published in 2020 at "Cancer Research"

DOI: 10.1158/1538-7445.sabcs19-gs4-03

Abstract: Background: The Clinical Treatment Score at 5 years (CTS5) is a prognostic tool using clinicopathological parameters (nodal status, tumor size, grade, and age) to estimate distant recurrence (DR) risk after 5 years of endocrine treatment… read more here.

Keywords: positive her2; treatment; tailorx study; cts5 ... See more keywords
Photo by sammiechaffin from unsplash

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.514

Abstract: 514 Background: The Clinical Treatment Score at 5 years (CTS5) is a prognostic tool using clinicopathological data to estimate distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women with estrogen receptor… read more here.

Keywords: risk late; unselected non; risk; cohort ... See more keywords
Photo by nci from unsplash

Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node-positive (N+) breast cancer patients with one to three positive nodes (N1).

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.555

Abstract: 555 Background: Identification of N+ breast cancer patients with a limited risk of recurrence improves selection of those for which chemotherapy and/or extended endocrine therapy (EET) may be most appropriate to reduce overtreatment. BCIN+ integrates… read more here.

Keywords: breast cancer; risk late; cts5; risk ... See more keywords